Molbio Diagnostics Limited
All news and filings related to Molbio Diagnostics Limited.
View all news & filings- High impact
Molbio Diagnostics Q1 FY27 Income at ₹411.5 Cr, EBITDA ₹103.7 Cr vs Loss in Q1 FY26
Molbio Diagnostics reported Q1 FY27 total income of ₹411.5 crore and EBITDA of ₹103.7 crore, a significant turnaround from a loss in Q1 FY26. PAT was ₹52.7 crore. This growth was driven by test-kit consumption. Export orders of ₹57 crore were deferred and recognized in Q1 FY27. The company is focusing on scaling up, R&D, and international expansion.
Read the summary - Low impact
Molbio Diagnostics Publishes Un-audited Financial Results for Q1 FY27
Molbio Diagnostics Limited published its un-audited financial results for the quarter ended June 30, 2026. The company is setting up a new workshop for diagnostic kits and X-ray equipment, with the first phase due by March 2027. Annual audits for FY26 have been completed and submitted.
Read the summary - High impact
Molbio Diagnostics Q1 FY27: Revenue ₹411.48 Cr, PAT ₹52.74 Cr, EBITDA ₹103.68 Cr
Molbio Diagnostics reported Q1 FY27 unaudited results with Total Income at ₹411.48 Cr, up from ₹100.47 Cr in Q1 FY26. EBITDA was ₹103.68 Cr (vs. loss of ₹14.50 Cr) and PAT was ₹52.74 Cr (vs. loss of ₹23.94 Cr). Truenat test-kit volume drove growth.
Read the summary - Low impact
Molbio Diagnostics Board Approves Q1 FY27 Un-audited Financial Results
Molbio Diagnostics' Board approved un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. Key Managerial Personnel have been authorized to determine event materiality and disclosures. The board meeting took place on September 5, 2026.
Read the summary - Low impact
Molbio Diagnostics Schedules Q1 FY27 Earnings Conference Call for Sep 8
Molbio Diagnostics Limited will host an Earnings Conference Call on September 8, 2026, at 4:00 PM IST to discuss financial performance for the quarter ended June 30, 2026. Key management personnel will participate in the call.
Read the summary - Low impact
Molbio Diagnostics Appoints Darshan Raghunath Karekar as Compliance Officer
Molbio Diagnostics Limited's Board Meeting on August 27, 2026, designated Mr. Darshan Raghunath Karekar as the Compliance Officer under SEBI (Prohibition of Insider Trading) Regulations, 2015. He already holds this position under Listing Regulations.
Read the summary - Low impact
Molbio Diagnostics Closes Trading Window from Aug 21 for Q1 FY27 Results
Molbio Diagnostics will close its trading window from August 21, 2026, until 48 hours post-declaration of Q1 FY27 unaudited financial results. This is in compliance with SEBI regulations.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio